Search
for
Sort by
Research 31–60 of 416
- Targeted therapy in melanoma
- Progress in Dermatology and Venereology in 2023 as reflected in the Journal of the European Academy of Dermatology and Venereology
- Regulatory mechanisms of LGR4 on cancer and cancer stem cell properties
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Self‐Assembled Peptide Hydrogels Loaded with Umbilical Cord‐Derived Mesenchymal Stem Cells Repairing Injured Endometrium and Restoring Fertility
- Biological therapy in the treatment of melanoma
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Dermatologic Adverse Events from Cancer Treatments
- Management of Toxicities of Targeted Therapies
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review
- Dermoscopy — 4th Conference of the Section of Dermoscopy and Other Skin Imaging Techniques (DiTOS) of the Polish Dermatological Society — Abstracts
- Procyanidin Oligomers Counteract TGF-β<sub>1</sub>- and TGF-β<sub>2</sub>-Induced Apoptosis in Hair Epithelial Cells: An Insight into Their Mechanisms
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- The PDGF/PDGFR pathway as a drug target
- The roles of Wnt/β‐catenin pathway in tissue development and regenerative medicine
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Perspectives in dermatopathology: telomeres and telomerase in ageing and cancer; with emphasis on cutaneous disease
- Exploring murE protein inhibitors of Tropheryma whipplei through pharmacoinformatic approaches incorporating solubility-enhancing formulation insights
- Abstracts
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor